1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. Beckley Psytech Acquires Eleusis Therapeutics

M&A Deal Summary

Beckley Psytech Acquires Eleusis Therapeutics

On October 24, 2022, Beckley Psytech acquired life science company Eleusis Therapeutics

Acquisition Highlights
  • This is Beckley Psytech’s 1st transaction in the Life Science sector.
  • This is Beckley Psytech’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2022-10-24
Target Eleusis Therapeutics
Sector Life Science
Buyer(s) Beckley Psytech
Deal Type Add-on Acquisition

Target

Eleusis Therapeutics

London, United Kingdom
Eleusis Therapeutics is a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design. Eleusis Therapeutics was 2013 and is based in London, United Kingdom.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Beckley Psytech

Oxford, United Kingdom
Category Company
Founded 2019
Sector Life Science
DESCRIPTION

Beckley Psytech is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Beckley Psytech was founded in 2019 and is based in Oxford, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2022 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal